Therefore, a new and effective treatment is needed for refractory anti‐MDA5 antibody‐positive CADM in patients with rapidly progressive interstitial pneumonia whose disease is not controlled by intensive treatment. This evidence concerns the gene IFIH1 and clinically amyopathic dermatomyositis.